Last €87.92 EUR
Change Today -0.274 / -0.31%
Volume 12.9K
As of 9:05 AM 03/6/15 All times are local (Market data is delayed by at least 15 minutes).

sanofi (SNW) Snapshot

Open
€88.11
Previous Close
€88.19
Day High
€88.29
Day Low
€87.22
52 Week High
09/30/14 - €89.91
52 Week Low
10/29/14 - €69.68
Market Cap
116.0B
Average Volume 10 Days
11.0K
EPS TTM
--
Shares Outstanding
1.3B
EX-Date
05/11/15
P/E TM
--
Dividend
€2.85
Dividend Yield
3.19%
Current Stock Chart for SANOFI (SNW)

sanofi (SNW) Details

Sanofi discovers, develops, and distributes therapeutic solutions. Its primary products include Lantus and Apidra analogs of human insulin; Insuman insulin solutions and suspensions; Amaryl, a sulfonylurea; Lyxumia, a prandial GLP-1 receptor agonist; BGStar, iBGStar, and MyStar Extra blood glucose meters; Cerezyme for Gaucher disease, Fabrazyme for Fabry, and Myozyme/Lumizyme for Pompe disease; Aldurazyme for mucopolysaccharidosis Type I; Aubagio for multiple sclerosis; and Lemtrada, a humanized monoclonal antibody. The company’s products also comprise Taxotere, a taxane derivative for cancers; Eloxatine for colorectal cancer; Jevtana for prostate cancer; Thymoglobulin, an immuno-suppressive and immuno-modulating agent; Mozobil stem cell mobilizer; and Zaltrap recombinant fusion protein. In addition, it offers thrombosis medicines, such as Plavix anti-platelet agent for atherothrombotic conditions and Lovenox to prevent and treat deep vein thrombosis; and cardiovascular medicines, including Multaq anti-arrhythmic agent and Aprovel/CoAprovel for hypertension treatments. Further, it provides Renagel/Renvela for patients with chronic kidney disease on dialysis to treat high phosphorus levels; Synvisc and Synvisc-One viscosupplements for pain associated with osteoarthritis; and pediatric and influenza, adult and adolescent booster, meningitis and pneumonia, and travel and endemics vaccines. In addition, the company provides pharmaceuticals and vaccines used by veterinarians, farmers, and pet owners; consumer health care products; and generic medicines. Sanofi distributes its products through its sales force, physicians, pharmacies, hospitals, distributors, veterinaries, chemists, and wholesalers. It has a strategic alliance with Illumina, Inc. to develop a next-generation sequencing based oncology test system. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.

Founded in 1973

sanofi (SNW) Top Compensated Officers

Chairman, Interim Chief Executive Officer, Ch...
Total Annual Compensation: €700.0K
Compensation as of Fiscal Year 2013.

sanofi (SNW) Key Developments

Genfit Reportedly Mulls Sale

Genfit SA (ENXTPA:GNFT) is reportedly exploring the option of selling itself. According to people familiar with the matter, Genfit SA has also held preliminary discussions with potential strategic buyers. According to the sources, Genfit has yet not made a any decision and there is a possibility that it may not sell at all. The potential buyers include Sanofi (ENXTPA:SAN), Shire plc (LSE:SHP) and Novartis AG (SWX:NOVN).

Sanofi Receives FDA Approval of Once-Daily Basal Insulin Toujeo

Sanofi announced that the U.S. Food and Drug Administration approved Toujeo, a once-daily long-acting basal insulin, to improve glycemic control in adults living with type 1 and type 2 diabetes. Toujeo is expected to be available in the U.S. at the beginning of second quarter 2015. The approval of Toujeo was based on FDA review of results from the EDITION clinical trial program, which was comprised of a series of international Phase III studies evaluating the efficacy and safety of Toujeo in more than 3,500 adults from broad and diverse diabetes populations. In the clinical trial program leading to approval, once-daily Toujeo was compared to that of once-daily Lantus in open-label, randomized, active-control, parallel, treat-to-target studies of up to 26 weeks of duration with 6 months safety extension. All studies of the EDITION program successfully met the primary study endpoints by demonstrating similar blood sugar control with Toujeo as compared to Lantus. The most common adverse events reported for Toujeo included nasopharyngitis and upper respiratory tract infection. Toujeo's Pharmacokinetic/Pharmacodynamic information and its rates of severe and documented symptomatic hypoglycemia can be found in the label. Toujeo will be available in the Toujeo SoloSTAR, a disposable prefilled pen which contains 450 units of Toujeo and requires one third of the injection volume to deliver the same number of insulin units as compared to the Lantus SoloSTAR. The maximum single injection dose of 80 IU meets the needs of the vast majority of patients on basal insulin in the U.S., who require 80 IU or less per day. Toujeo is currently pending marketing authorization with the European Medicines Agency and other health authorities around the world.

Sanofi Presents at 3rd Annual SACHS Cancer Bio Partnering and Investment Forum, Feb-23-2015 09:55 AM

Sanofi Presents at 3rd Annual SACHS Cancer Bio Partnering and Investment Forum, Feb-23-2015 09:55 AM. Venue: The New York Academy of Sciences, 7 World Trade Center, 250 Greenwich St, 40th Floor (D Elevator Bank), New York, NY10007, United States. Speakers: Raffaele Baffa, Senior Director, Translational and Experimental Medicine.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SNW:GR €87.92 EUR -0.274

SNW Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Amgen Inc $159.60 USD 0.00
Bayer AG €133.35 EUR -0.012
Bristol-Myers Squibb Co $66.05 USD 0.00
Gilead Sciences Inc $103.42 USD 0.00
GlaxoSmithKline PLC 1,565 GBp -6.50
View Industry Companies
 

Industry Analysis

SNW

Industry Average

Valuation SNW Industry Range
Price/Earnings 24.0x
Price/Sales 3.1x
Price/Book 1.9x
Price/Cash Flow 15.4x
TEV/Sales 2.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SANOFI, please visit www.sanofi.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.